{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"66.8551","value":"11.085"},{"groupId":"OG001","spread":"0.4888","value":"0.061"}]}],"title":"Pre-infusion - dose (Cmin) (n: 76, 64)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"971.3057","value":"867.147"},{"groupId":"OG001","spread":"1145.860","value":"1068.51"}]}],"title":"End of infusion (Cmax) (n: 58, 49)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"64"}],"units":"Participants"}],"description":"Pre-infusion (Cmin) and end of infusion (C2h) vinorelbine PK blood samples were collected at Cycle 2 Day 1. Only valid vinorelbine PK blood samples collected at steady state were used in the analyses.","dispersionType":"Standard Deviation","groups":[{"description":"Oral everolimus of 5 mg/day","id":"OG000","title":"Everolimus"},{"description":"Oral placebo everolimus of 5 mg/day","id":"OG001","title":"Everolimus Placebo"}],"paramType":"MEAN","populationDescription":"The Safety Set consisted of all patients who received at least one dose of the study treatment and who had at least one valid post-baseline safety assessment.","reportingStatus":"POSTED","timeFrame":"Cycle 2, Day 1","title":"Vinorelbine Blood Concentrations by Leading Dose and Time Point","type":"SECONDARY","unitOfMeasure":"ng/ml"}